UK5099 Inhibits the NLRP3 Inflammasome Independently of its Long‐Established Target Mitochondrial Pyruvate Carrier
Advanced Science · 2024-09 · 11 (33)
DOI: 10.1002/advs.202307224 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024-07. Verfasst von Linyu Ran und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, 200120, China. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Science and Technology Commission, Shanghai Pujiang Program.
Abstract (Originalsprache)
Targeting NLRP3 inflammasome has been recognized as a promising therapeutic strategy for the treatment of numerous common diseases. UK5099, a long‐established inhibitor of mitochondrial pyruvate carrier (MPC), is previously found to inhibit macrophage inflammatory responses independent of MPC expression. However, the mechanisms by which UK5099 inhibit inflammatory responses remain unclear. Here, it is shown that UK5099 is a potent inhibitor of the NLRP3 inflammasome in both mouse and human primary macrophages. UK5099 selectively suppresses the activation of the NLRP3 but not the NLRC4 or AIM2 inflammasomes. Of note, UK5099 retains activities on NLRP3 in macrophages devoid of MPC expression, indicating this inhibitory effect is MPC‐independent. Mechanistically, UK5099 abrogates mitochondria‐NLRP3 interaction and in turn inhibits the assembly of the NLRP3 inflammasome. Further, a single dose of UK5099 persistently reduces IL‐1β production in an endotoxemia mouse model. Importantly, structure modification reveals that the inhibitory activities of UK5099 on NLRP3 are unrelated to the existence of the activated double bond within the UK5099 molecule. Thus, this study uncovers a previously unknown molecular target for UK5099, which not only offers a new candidate for the treatment of NLRP3‐driven diseases but also confounds its use as an MPC inhibitor in immunometabolism studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, 200120, China.
- Medical College, Tongji University, Shanghai, 200092, China.
- Department of Emergency, The First Affiliated Hospital of Hainan Medical University, Haikou, Hainan, 570102, China.
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, 55902, USA.
- Center for Regenerative Medicine, Mayo Clinic, Rochester, MN, 55902, USA.
- Department of Medicinal Chemistry, School of Pharmacy, Fudan University, 826 Zhangheng Rd, Shanghai, 201203, China.
ORCID-Profile: Feilong Wang
Förderung
- National Natural Science Foundation of China
- Shanghai Science and Technology Commission
- Shanghai Pujiang Program
- the Top-level Clinical Discipline Project of Shanghai Pudong
Zitieren
APA
Ran, L., Chen, M., Ye, J., Zhang, S., Luo, Z., Bai, T., Qian, C., Zhou, Q., Shan, M., Chu, Y., Herrmann, J., Li, Q., & Wang, F. (2024). UK5099 Inhibits the NLRP3 Inflammasome Independently of its Long‐Established Target Mitochondrial Pyruvate Carrier. Advanced Science, 11(33). https://doi.org/10.1002/advs.202307224
Vancouver
Ran L, Chen M, Ye J, Zhang S, Luo Z, Bai T, et al. UK5099 Inhibits the NLRP3 Inflammasome Independently of its Long‐Established Target Mitochondrial Pyruvate Carrier. Advanced Science. 2024;11(33). doi:10.1002/advs.202307224
BibTeX
@article{Ran2024,
author = {Ran, Linyu and Chen, Miao and Ye, Jihui and Zhang, Song and Luo, Zhibing and Bai, Tengfei and Qian, Chenchen and Zhou, Quan and Shan, Mengtian and Chu, Yong and Herrmann, Joerg and Li, Qiang and Wang, Feilong},
title = {UK5099 Inhibits the NLRP3 Inflammasome Independently of its Long‐Established Target Mitochondrial Pyruvate Carrier},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {33},
doi = {10.1002/advs.202307224}
}
EUVIMED